<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1546-0096-6-S1-P10</ui>
   <ji>1546-0096</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>CD39: a regulatory role in childhood arthritis</p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Moncrieffe</snm>
               <fnm>H</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Nistala</snm>
               <fnm>K</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Hunter</snm>
               <fnm>P</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Kamhieh</snm>
               <fnm>Y</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Wedderburn</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Institute of Child Health, UCL, London, UK</p>
            </ins>
         </insg>
         <source>Pediatric Rheumatology</source>
         <supplement>
            <title>
               <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p>
            </title>
            <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Micha&#235;l Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor>
            <note>Meeting abstracts &#8211; A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note>
         </supplement>
         <conference>
            <title>
               <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p>
            </title>
            <location>London, UK</location>
            <date-range>14&#8211;17 September 2008</date-range>
            <url>http://www.pres.org.uk</url>
         </conference>
         <issn>1546-0096</issn>
         <pubdate>2008</pubdate>
         <volume>6</volume>
         <issue>Suppl 1</issue>
         <fpage>P10</fpage>
         <url>http://www.ped-rheum.com/content/6/S1/P10</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1546-0096-6-S1-P10</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>15</day>
               <month>9</month>
               <year>2008</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2008</year>
         <collab>Moncrieffe et al; licensee BioMed Central Ltd.</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>Human regulatory T cells (T reg) are classically defined as CD4+ CD25hi Foxp3+. There is increasing evidence that T cells may be subject to regulation via the conversion of proinflammatory ATP to anti-inflammatory adenosine. Methotrexate, the standard therapy for children with JIA, is proposed to work via this mechanism. CD39 belongs to a family of ectoenzymes that convert ATP into an adenosine precursor. ATPase activity may therefore represent an important regulatory mechanism in JIA.</p>
      </sec>
      <sec>
         <st>
            <p>Materials and methods</p>
         </st>
         <p>Mononuclear cells from peripheral blood (PBMC) and synovial fluid (SFMC) of patients with JIA were analysed in parallel with PBMC from healthy controls. Samples were analysed by 5-colour flow cytometry for expression of Foxp3, CD25 and CD39. FACS sorted cells were assayed for ATPase activity.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>CD39 expression was demonstrated on a variety of mononuclear cells in both controls and JIA patients. Increased expression of CD39 was seen on SFMC. Mononuclear cells expressing CD39 showed rapid ATPase activity in vitro. We characterise a proportion of CD39+ T cells with a memory phenotype, express Foxp3 and have regulatory function.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>ATPase activity may represent a novel mechanism by which regulation may occur in JIA. CD39+ CD4 cells are enriched in the joint in JIA. CD4+ T cells which express both CD39 and Foxp3 may represent a population with the capability to regulate via multiple mechanisms and therefore be more potent suppressors.</p>
      </sec>
   </bdy>
</art>
